Effect of collaborative care between traditional and faith healers and primary health-care workers on psychosis outcomes in Nigeria and Ghana (COSIMPO): a cluster randomised controlled trial.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
29 08 2020
Historique:
received: 09 10 2019
revised: 10 02 2020
accepted: 11 03 2020
entrez: 31 8 2020
pubmed: 31 8 2020
medline: 21 10 2020
Statut: ppublish

Résumé

Traditional and faith healers (TFH) provide care to a large number of people with psychosis in many sub-Saharan African countries but they practise outside the formal mental health system. We aimed to assess the effectiveness and cost-effectiveness of a collaborative shared care model for psychosis delivered by TFH and primary health-care providers (PHCW). In this cluster-randomised trial in Kumasi, Ghana and Ibadan, Nigeria, we randomly allocated clusters (a primary care clinic and neighbouring TFH facilities) 1:1, stratified by size and country, to an intervention group or enhanced care as usual. The intervention included a manualised collaborative shared care delivered by trained TFH and PHCW. Eligible participants were adults (aged ≥18 years) newly admitted to TFH facilities with active psychotic symptoms (positive and negative syndrome scale [PANSS] score ≥60). The primary outcome, by masked assessments at 6 months, was the difference in psychotic symptom improvement as measured with the PANSS in patients in follow-up at 3 and 6 months. Patients exposure to harmful treatment practices, such as shackling, were also assessed at 3 and 6 months. Care costs were assessed at baseline, 3-month and 6-month follow-up, and for the entire 6 months of follow-up. This trial was registered with the National Institutes of Health Clinical Trial registry, NCT02895269. Between Sept 1, 2016, and May 3, 2017, 51 clusters were randomly allocated (26 intervention, 25 control) with 307 patients enrolled (166 [54%] in the intervention group and 141 [46%] in the control group). 190 (62%) of participants were men. Baseline mean PANSS score was 107·3 (SD 17·5) for the intervention group and 108·9 (18·3) for the control group. 286 (93%) completed the 6-month follow-up at which the mean total PANSS score for intervention group was 53·4 (19·9) compared with 67·6 (23·3) for the control group (adjusted mean difference -15·01 (95% CI -21·17 to -8·84; 0·0001). Harmful practices decreased from 94 (57%) of 166 patients at baseline to 13 (9%) of 152 at 6 months in the intervention group (-0·48 [-0·60 to -0·37] p<0·001) and from 59 (42%) of 141 patients to 13 (10%) of 134 in the control group (-0·33 [-0·45 to -0·21] p<0·001), with no significant difference between the two groups. Greater reductions in overall care costs were seen in the intervention group than in the control group. At the 6 month assessment, greater reductions in total health service and time costs were seen in the intervention group; however, cumulative costs over this period were higher (US $627 per patient vs $526 in the control group). Five patients in the intervention group had mild extrapyramidal side effects. A collaborative shared care delivered by TFH and conventional health-care providers for people with psychosis was effective and cost-effective. The model of care offers the prospect of scaling up improved care to this vulnerable population in settings with low resources. US National Institute of Mental Health.

Sections du résumé

BACKGROUND
Traditional and faith healers (TFH) provide care to a large number of people with psychosis in many sub-Saharan African countries but they practise outside the formal mental health system. We aimed to assess the effectiveness and cost-effectiveness of a collaborative shared care model for psychosis delivered by TFH and primary health-care providers (PHCW).
METHODS
In this cluster-randomised trial in Kumasi, Ghana and Ibadan, Nigeria, we randomly allocated clusters (a primary care clinic and neighbouring TFH facilities) 1:1, stratified by size and country, to an intervention group or enhanced care as usual. The intervention included a manualised collaborative shared care delivered by trained TFH and PHCW. Eligible participants were adults (aged ≥18 years) newly admitted to TFH facilities with active psychotic symptoms (positive and negative syndrome scale [PANSS] score ≥60). The primary outcome, by masked assessments at 6 months, was the difference in psychotic symptom improvement as measured with the PANSS in patients in follow-up at 3 and 6 months. Patients exposure to harmful treatment practices, such as shackling, were also assessed at 3 and 6 months. Care costs were assessed at baseline, 3-month and 6-month follow-up, and for the entire 6 months of follow-up. This trial was registered with the National Institutes of Health Clinical Trial registry, NCT02895269.
FINDINGS
Between Sept 1, 2016, and May 3, 2017, 51 clusters were randomly allocated (26 intervention, 25 control) with 307 patients enrolled (166 [54%] in the intervention group and 141 [46%] in the control group). 190 (62%) of participants were men. Baseline mean PANSS score was 107·3 (SD 17·5) for the intervention group and 108·9 (18·3) for the control group. 286 (93%) completed the 6-month follow-up at which the mean total PANSS score for intervention group was 53·4 (19·9) compared with 67·6 (23·3) for the control group (adjusted mean difference -15·01 (95% CI -21·17 to -8·84; 0·0001). Harmful practices decreased from 94 (57%) of 166 patients at baseline to 13 (9%) of 152 at 6 months in the intervention group (-0·48 [-0·60 to -0·37] p<0·001) and from 59 (42%) of 141 patients to 13 (10%) of 134 in the control group (-0·33 [-0·45 to -0·21] p<0·001), with no significant difference between the two groups. Greater reductions in overall care costs were seen in the intervention group than in the control group. At the 6 month assessment, greater reductions in total health service and time costs were seen in the intervention group; however, cumulative costs over this period were higher (US $627 per patient vs $526 in the control group). Five patients in the intervention group had mild extrapyramidal side effects.
INTERPRETATION
A collaborative shared care delivered by TFH and conventional health-care providers for people with psychosis was effective and cost-effective. The model of care offers the prospect of scaling up improved care to this vulnerable population in settings with low resources.
FUNDING
US National Institute of Mental Health.

Identifiants

pubmed: 32861306
pii: S0140-6736(20)30634-6
doi: 10.1016/S0140-6736(20)30634-6
pmc: PMC8473710
mid: NIHMS1626802
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02895269']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

612-622

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NIMH NIH HHS
ID : U19 MH098718
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

Transcult Psychiatry. 2013 Jun;50(3):433-41
pubmed: 23740893
Lancet. 2013 Nov 9;382(9904):1575-86
pubmed: 23993280
Int J Ment Health Syst. 2012 Sep 08;6(1):13
pubmed: 22958505
Int J Ment Health Syst. 2008 Jun 16;2(1):8
pubmed: 18554420
Soc Psychiatry Psychiatr Epidemiol. 2018 Jun;53(6):555-566
pubmed: 29696304
Lancet. 2001 Apr 14;357(9263):1191-4
pubmed: 11323066
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Bull World Health Organ. 2010 Nov 1;88(11):815-23
pubmed: 21076562
Lancet Psychiatry. 2016 Feb;3(2):154-70
pubmed: 26851329
Lancet Psychiatry. 2015 Feb;2(2):168-77
pubmed: 26359753
J Ethnobiol Ethnomed. 2007 Jan 26;3:6
pubmed: 17257409
Soc Psychiatry Psychiatr Epidemiol. 2019 Mar;54(3):395-403
pubmed: 30456425
Nat Hum Behav. 2018 Jan;2(1):6-10
pubmed: 30980045
Br J Psychiatry Suppl. 2000;(39):s28-33
pubmed: 10945075
Soc Psychiatry Psychiatr Epidemiol. 2000 Oct;35(10):480-5
pubmed: 11127723
Afr Health Sci. 2009 Aug 1;9 Suppl 1:S16-22
pubmed: 20589155
Qual Health Res. 2017 Dec;27(14):2177-2188
pubmed: 28901831
Early Interv Psychiatry. 2016 Feb;10(1):54-62
pubmed: 24690088
Soc Psychiatry Psychiatr Epidemiol. 1997 May;32(4):215-21
pubmed: 9184467
Trials. 2017 Oct 10;18(1):462
pubmed: 29017605
Br J Psychiatry. 2005 May;186:436-41
pubmed: 15863750
Schizophr Res. 2000 Mar 16;42(1):67-77
pubmed: 10706987
PLoS One. 2016 Sep 12;11(9):e0162305
pubmed: 27618551
Bull World Health Organ. 2000;78(2):252-7
pubmed: 10743298
Psychiatry Res. 2003 Nov 1;121(1):31-49
pubmed: 14572622
Br J Psychiatry. 2018 Jan;212(1):34-41
pubmed: 29433613

Auteurs

Oye Gureje (O)

WHO Collaborating Centre for Research and Training in Mental Health, Neurosciences and Substance Abuse, Department of Psychiatry, University of Ibadan, Ibadan, Nigeria. Electronic address: ogureje@com.ui.edu.ng.

John Appiah-Poku (J)

Department of Behavioural Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

Toyin Bello (T)

WHO Collaborating Centre for Research and Training in Mental Health, Neurosciences and Substance Abuse, Department of Psychiatry, University of Ibadan, Ibadan, Nigeria.

Lola Kola (L)

WHO Collaborating Centre for Research and Training in Mental Health, Neurosciences and Substance Abuse, Department of Psychiatry, University of Ibadan, Ibadan, Nigeria.

Ricardo Araya (R)

Department of Health Services and Population Research, King's College London, London, UK.

Dan Chisholm (D)

Department of Mental Health and Substance Abuse, WHO, Geneva, Switzerland.

Oluyomi Esan (O)

WHO Collaborating Centre for Research and Training in Mental Health, Neurosciences and Substance Abuse, Department of Psychiatry, University of Ibadan, Ibadan, Nigeria.

Benjamin Harris (B)

Department of Psychiatry, University of Liberia, Monrovia, Liberia.

Victor Makanjuola (V)

WHO Collaborating Centre for Research and Training in Mental Health, Neurosciences and Substance Abuse, Department of Psychiatry, University of Ibadan, Ibadan, Nigeria.

Caleb Othieno (C)

Department of Psychiatry, University of Nairobi, Nairobi, Kenya.

LeShawndra Price (L)

Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD, USA.

Soraya Seedat (S)

Department of Psychiatry, Stellenbosch University, Cape Town, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH